ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1341	National Cancer Institute	Html	en	Smokeless Tobacco and Cancer	A fact sheet about the health risks associated with the use of smokeless tobacco.	tobacco cut size 0.465919 NCI smoking cessation 0.353151 safe level 0.345736 oral tobacco 0.470575 nicotine addiction 0.363201 Human Services 0.340767 Health State-of-the-Science conference 0.343313 U.S. Department 0.340786 tobacco-specific nitrosamines 0.373338 tobacco fertilizer 0.451995 advisory committee 0.346137 powdered tobacco 0.462627 Health Organization International 0.342988 oral cancer 0.332186 National Institutes 0.343448 Watson C. Surveillance 0.3381 Tobacco Control Monograph 0.451686 moist snuff 0.436686 precancerous white patches 0.344838 International Agency 0.339252 NCI’s Smoking 0.334129 Tobacco Research 0.437462 NCI fact sheet 0.385333 lower lip 0.34967 esophageal cancer 0.332063	nicotine stays 0.353085 Yes. All tobacco 0.450832 National Cancer Institute 0.373261 LiveHelp online chat 0.341688 American snuff 0.346643 polynuclear aromatic hydrocarbons 0.347124 Eastern time 0.340428 spitting tobacco 0.470917 online text chat 0.340605 polycyclic aromatic hydrocarbons 0.346589 smokeless tobacco products 0.615213 smokeless tobacco cause 0.576883 Nicotine content 0.350271 un-ionized nicotine 0.348074 Surgeon General 0.344959 smokeless tobacco 0.995709 Yes. Smokeless tobacco 0.55885 dry snuff 0.363969 noncancerous oral conditions 0.343638 NIH State-of-the-Science Panel 0.338818 tobacco cause cancer 0.483342 smoking cessation counselor 0.38611 tobacco juices 0.469352 harmful chemicals 0.350583	CLICK HERE
1351	National Cancer Institute	Html	en	Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of osteosarcoma and malignant fibrous histiocytoma of bone.	high-grade osteosarcoma patients 0.629145 co-operative German-Austrian-Swiss osteosarcoma 0.55607 neoadjuvant cooperative osteosarcoma 0.624122 pediatric osteosarcoma 0.57965 locally recurrent osteosarcoma 0.5543 Primary high-grade osteosarcoma 0.612176 parosteal osteosarcoma 0.568181 conventional osteosarcoma 0.56726 High grade osteosarcoma 0.599621 cooperative osteosarcoma study 0.792783 nonmetastatic osteosarcoma 0.60813 german-austrian-swiss osteosarcoma study 0.647756 high-grade osteosarcoma 0.738641 craniofacial osteosarcoma 0.630712 conventional high-grade osteosarcoma 0.570688 patients 0.646684 radiation-associated craniofacial osteosarcoma 0.580431 European Osteosarcoma Intergroup 0.58771 osteosarcoma incidence rate 0.594537 neoadjuvant chemotherapy 0.670909 high-grade extremity osteosarcoma 0.5876 Extraskeletal osteosarcoma 0.568579 Craniofacial osteosarcoma Experience 0.589537 Group Osteosarcoma Study 0.569569 radiation-related osteosarcoma 0.565185	osteosarcoma skip metastases 0.57865 synchronous multifocal osteosarcoma 0.617106 Osteosarcoma Intergroup study 0.567726 et al. 0.76197 PUBMED Abstract 0.575849 unresectable high-grade osteosarcoma 0.562489 primary osteosarcoma 0.586929 periosteal osteosarcoma 0.560798 osteosarcoma study group 0.793978 recurrent osteosarcoma 0.571668 non-metastatic osteosarcoma 0.633808 multi-institutional osteosarcoma study 0.604239 extremity osteosarcoma 0.634474 metastatic osteosarcoma 0.602383 multiinstitutional osteosarcoma study 0.587612 Abstract 0.808529 Clin Oncol 0.842874 operable osteosarcoma 0.589711 cooperative german-austrian-swiss osteosarcoma 0.615008 primary tumor 0.561916 intermediate-grade osteosarcoma 0.59029 Oncology Group 0.566747 cancer 0.596697 osteosarcoma 0.959056	CLICK HERE
1499	National Cancer Institute	Html	en	Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer.	hemiparanasal sinus 0.501642 cure rates 0.493854 positive nodes 0.488668 standard treatment schedules 0.549584 Nodal involvement 0.497639 cancer deaths 0.490757 small percentage 0.485324 paranasal sinuses 0.76526 operable tumors 0.521562 PDQ cancer information 0.674275 (es). 0.507032 T1 mucosal carcinomas 0.579667 neck radiation therapy 0.604078 cancer information summary 0.645943 frequent type 0.494315 high doses 0.481624 Squamous cell carcinoma 0.582109 breast cancer prevention 0.543533 direct extension 0.48751 malignant degeneration 0.512598 advanced carcinomas 0.493525 ethmoid sinuses 0.558752 NCI’s PDQ 0.512104 NCI PDQ cancer 0.582736 paranasal sinus cancers 0.63814	radical surgery 0.487234 frontal sinuses 0.560784 radiation therapy 0.931486 low-grade benign tumor 0.581394 maxillary sinus 0.511122 locoregional recurrence accounts 0.563108 nasal vestibule 0.506572 Lymph nodes 0.492664 vital areas 0.483188 distant metastases 0.516432 bony confines 0.499241 malignant tumor 0.600994 PDQ documents 0.510902 early tumors 0.514544 radical radiation therapy 0.591316 advanced disease 0.493565 nasal cavity 0.593061 treatment volume 0.481814 local disease 0.484616 tumors 0.539577 stage III tumors 0.513203 neck cancer 0.495811 postoperative radiation therapy 0.591777 adjacent structures. 0.488857	CLICK HERE
1599	National Cancer Institute	Html	en	Selected Vegetables/Sun's Soup (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of selected vegetables/Sun's soup as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	General Information section 0.439986 phase I/II 0.372901 soup 0.641588 eligible patients 0.381172 United States 0.398891 Human/Clinical Studies section 0.504014 standard laboratory chow 0.498456 advanced non-small cell 0.617549 toxicity arm 0.381025 control group 0.47167 Sun’s Soup 0.39938 cell lung cancer. 0.443882 Soup treatment group. 0.419226 fed standard laboratory 0.408383 conventional therapy 0.380328 Vegetables/Sun’s Soup 0.633353 dietary supplements 0.390642 tumor growth 0.410892 percent body-weight loss 0.372171 lymph node metastasis 0.373015 average KPS score 0.387592 barbat skullcap 0.397578 cancer information summary 0.38735 patent document 0.416332	clinical trial 0.401308 mung bean 0.484404 barbata D. Don 0.434127 best supportive care 0.383219 shiitake mushroom 0.46504 patients 0.656235 primary tumor 0.381698 Selected Vegetables/Sun 0.926979 Scutellaria barbata D. 0.437829 KPS score 0.444385 non-small cell lung 0.820617 survival arm 0.438189 Phaseolus radiatus L. 0.435744 nonconsecutive case series 0.385568 median survival time 0.500228 cell lung cancer 0.65934 study entry 0.475867 Soup treatment group 0.54526 radiation therapy 0.522928 Hedyotis diffusa Willd. 0.437904 mice fed standard 0.407302 Soup dietary supplement 0.400111 I/II clinical trial 0.398282	CLICK HERE
1617	National Cancer Institute	Html	en	Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.	red blood cells 0.746761 chronic idiopathic myelofibrosis 0.40092 cancer treatment 0.416363 primary myelofibrosis 0.53957 PDQ cancer information 0.430215 bone marrow aspiration 0.385705 clinical trial search 0.421224 white blood cells 0.676519 chronic eosinophilic leukemia 0.451961 blood cells increases 0.444984 clinical trials 0.768861 chronic neutrophilic leukemia 0.40279 mature blood cells 0.434847 fewer blood cells 0.406923 cancer information summary 0.401424 clinical trial 0.500574 early signs 0.377313 patients 0.431687 blood cells 0.902472 blood vessels 0.37721 chronic myelogenous leukemia 0.406738 Treatment Editorial Board 0.377482 essential thrombocythemia 0.420345 treatment 0.55278 stored stem cells 0.37624	immature blood cells 0.399031 blood stem cell 0.37725 cancer cells 0.408902 -fighting blood cells 0.405086 lymphoid stem cell 0.374191 specific cancer cells 0.392312 chronic myeloproliferative neoplasms 0.69658 signs 0.38226 polycythemia vera 0.418683 patient 0.388228 treatment clinical trials 0.396123 blood stem cells 0.497004 National Cancer Institute 0.457233 routine blood test 0.45249 new treatment 0.393316 white blood cell 0.399685 extra blood cells 0.469808 bone marrow 0.605562 PDQ summary 0.382577 cancer clinical trials 0.425229 blood clots 0.392843 cancer 0.517448 information 0.439199 Myelogenous Leukemia Treatment 0.387746	CLICK HERE
1694	National Cancer Institute	Html	en	Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version	Childhood central nervous system (CNS) germ cell tumors form from germ cells (a type of cell that forms as a fetus develops and later becomes sperm in the testicles or eggs in the ovaries). Learn about the signs, tests to diagnose, and treatment of pediatric germ cell tumors in the brain in this expert-reviewed summary.	tumor marker levels 0.3628 cancer treatment 0.421684 Cell Tumors Treatment 0.421872 tumor marker 0.418943 blood tumor marker 0.368072 tumor marker tests 0.401497 germ cell tumor 0.574325 chemotherapy 0.377281 following PDQ summaries 0.365055 PDQ cancer information 0.426073 clinical trials 0.64034 Pediatric Treatment Editorial 0.365107 cancer information summary 0.398144 clinical trial 0.507274 childhood cns 0.519486 tumor markers 0.382879 CNS germ cell 0.581589 Extracranial Germ Cell 0.410121 different types 0.371541 NCI PDQ cancer 0.369493 radiation therapy 0.586685 Treatment Editorial Board 0.36802 Cord Tumors Treatment 0.393052 late effects 0.370411 treatment 0.581174	cancer cells 0.438925 treatment clinical trial 0.368062 PDQ Pediatric Treatment 0.363419 nervous system germ 0.412082 treatment clinical trials 0.389618 National Cancer Institute 0.397655 diagnose childhood CNS 0.382168 spinal cord 0.499499 tumor cells 0.386305 Germ cells tumors 0.441556 new treatment 0.423148 high tumor marker 0.363373 childhood cancer information 0.366666 external radiation therapy 0.366121 brain 0.390174 PDQ summary 0.396735 germ cell tumors 0.941151 cells 0.445231 cancer clinical trials 0.367524 stem cell rescue 0.36994 cancer 0.582086 standard treatment 0.367712 tumor marker level 0.399336 spinal cord tumors 0.390737	CLICK HERE
2050	National Cancer Institute	Html	es	Análisis del antígeno prostático específico (PSA)	Hoja informativa sobre la prueba del antígeno prostático específico (PSA) y los exámenes selectivos de detección para el cáncer de próstata, y clarifica los beneficios y limitaciones de dicha prueba.	posibles complicaciones 0.529476 United States Preventive 0.549836 hiperplasia prostática benigna 0.569875 fusión génica tmprss2-erg 0.5485 estudio plco 0.535774 PLCO trials 0.538088 eréctil o incontinencia 0.532144 médico quizás 0.54755 ng per milliliter 0.54786 concentration-based assay 0.526257 Pauler DK 0.526835 structure-based isopsa assay 0.54715 estudio clínico plco 0.561758 tanta lentitud 0.531594 posibles perjuicios 0.59922 riesgos y beneficios 0.531533 Servicios Preventivos 0.526931 European Randomised Study 0.54659 hiperplasia benigna 0.602949 Preventive Health Services 0.541802 llamadas isoformas 0.529743 Screening Draft Recommendations 0.555159	Hugosson J 0.571924 espectro de  isoformas 0.553214 Instituto Nacional 0.525806 próstata en asociación 0.528933 PSA quizás 0.924082 posibles efectos 0.527227 Internal Medicine 0.527548 Services Task Force 0.63375 among men with 0.545229 estados benignos 0.530298 agrandamiento benigno 0.537792 PubMed Abstract 0.784346 prostate cancer 0.975142 estadio inicial quizás 0.562336 obstante exámenes 0.563732 New England Journal 0.630867 Goodman PJ 0.525307 de 1 muerte 0.528041 Roobol MJ 0.576631 pequeños tumores 0.530536 Heijnsdijk EAM 0.527351 Hafron JM 0.526062	CLICK HERE
3440	National Cancer Institute	Html	es	Exámenes de detección del neuroblastoma (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el neuroblastoma.	Visuals Online 0.563675 PDQ Exámenes 0.77452 Physician Data Query 0.971175 ecografía fetal 0.642315 prevención revisa 0.581226 graves riesgos 0.622769	presente síntomas 0.605798 información ayuda 0.590632 cuáles tipos 0.60865 National Cancer Institute 0.613572 siguientes riesgos 0.582879 Instituto Nacional 0.71673	CLICK HERE
3851	National Cancer Institute	Html	en	Treating Cancer without Harming the Heart	Researchers from the fields of oncology and cardiology are working to find ways to prevent, manage, and possibly even reverse the cardiovascular side effects of certain cancer therapies.	childhood cancers 0.722954 cardiovascular changes 0.633513 cancer treatment-related cardiotoxicity 0.773654 ischemic heart disease 0.641571 research 0.740587 task force 0.629922 childhood cancer increases 0.668587 cardiac health 0.652664 heart problems 0.663961 heart failure 0.684862 risk factors 0.812151 certain cardiac functions 0.66508 Community Oncology Research 0.635145 ischemic cardiac disease 0.673041 breast cancer patients 0.750275 adult survivors 0.677672 heart 0.763054 breast cancer trial 0.667286 Prevention Trials Research 0.631942 radiation therapy 0.716677 childhood cancer 0.74187 cancer treatments 0.731665 childhood cancer treatments 0.686861 study 0.637136	community oncology 0.686779 cancer treatment—chemotherapy agents 0.673113 cardiac side effects 0.698632 Anderson Cancer Center 0.750363 early cardiac dysfunction 0.678902 new research strategies 0.65852 trastuzumab-related cardiac events 0.724465 Dana-Farber Cancer Institute 0.652906 Community Oncology Cardiotoxicity 0.640076 cardiac risk factors 0.767014 subsequent research agendas 0.636051 cardiac adverse effects 0.710556 MD Anderson Cancer 0.75179 cardiac arrhythmia 0.64223 NCI Community Oncology 0.685131 NCI-supported cardiotoxicity studies 0.649029 breast cancer 0.957268 treatment-induced cardiac disease 0.677462 NCI community-based oncology 0.638369 breast cancer treatments 0.671567 Vanderbilt-Ingram Cancer Center 0.655353 cancer clinical trials 0.814235 underlying cardiovascular risk 0.658241 cardiovascular problems 0.640023	CLICK HERE
16851	National Cancer Institute	Html	es	Sulfato de hidracina (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso del sulfato de hidracina como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Centro Nacional 0.533358 determinados efectos 0.530508 New Hampshire Avenue 0.523784 siguientes aspectos 0.523737 Drug Administration 0.514799 patients with weight 0.533925 NCI Best Case 0.549835 diagnosed non-small-cell lung 0.536234 Grosvenor M 0.517103 datos bibliográficos pubmed 0.525622 siguientes preguntas 0.515807 Heber D 0.517667 siguientes riesgos 0.519241 Instituto Nacional 0.7207 Su JQ 0.518581 Salud Complementaria 0.556196 Visuals Online 0.516984 siguientes resultados 0.521312 curso estudios 0.529991 complementarias revisa 0.524603	Clin Oncol 0.521025 Physician Data Query 0.597613 Goldberg RM 0.517983 PDQ Sulfato 0.709455 Estados Unidos 0.833671 Chlebowski RT 0.553534 breakdown measured 0.519564 libre uso 0.517176 compañía farmacéutica 0.520309 página manejo 0.515736 ¿El tratamiento 0.532073 Bulcavage L 0.518136 patients with 0.551924 siguientes datos 0.520348 ¿Los beneficios 0.514828 juntos cam 0.514239 Funcionamiento motor 0.518326 Tayek JA 0.519355 Series Program 0.514501 medicina complementaria 0.982503	CLICK HERE